🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We recently published an article in BMJ Neurology Open on the rationale and design of our Phase 1b/2a #ClinicalTrial evaluating the potential of our antigen-specific immune tolerance treatment in development for #MyastheniaGravis (MG). Read here: bit.ly/3DMGvrk

The U.S. FDA has cleared the Investigational New Drug (IND) application for CNP-103, our #nanoparticle in development to address the underlying autoimmunity of #Type1Diabetes (#T1D) via antigen-specific immune tolerance. Read our press release: bit.ly/4hooAGh

In this @BioSpace article, our CEO Dannielle Appelhans highlights why Chicago is a rising biotech hub—offering top talent, scientific expertise, and growth potential. Read more about the life sciences momentum in our area: bit.ly/3CuNYet

Adam Elhofy, PhD, our VP, Research, and Joe Podojil, PhD, Director, Immunology, will present at the 8th Antigen-Specific Immune Tolerance Summit. Join us for discussions about our #nanoparticles in development for #PrimaryBiliaryCholangitis and #T1D: as-immunetolerance.com/whats-on/speak…

Our CEO, Dannielle Appelhans, recently spoke to BioSpace's Annalee Armstrong about our clinical progress in #PrimaryBiliaryCholangitis, #Type1Diabetes, and #MyastheniaGravis. Check out the article in the post below for details from their conversation.

We are now #GPTWCertified. This reflects our commitment to a supportive, collaborative workplace as we work to transform the future of #AutoimmuneDisease treatment with our platform for antigen-specific immune tolerance. Learn more: bit.ly/4gR91WE #GreatPlaceToWork

We are working to reprogram the immune system and restore lives with our next-generation, disease-modifying therapies. During #AutoimmuneDiseaseAwarenessMonth, we join the 23M+ people living with #AutoimmuneDiseases in the United States who are raising #AutoimmuneAwareness.

We are advancing nanoparticles developed with our platform for antigen-specific immune tolerance. We aim to reprogram the immune system to treat #AutoimmuneDiseases without broad immunosuppression. Read more in this article by gail dutton in Genetic Engineering & Biotechnology News: bit.ly/43kz1q7

Next week, our Chief Medical Officer, Paul Peloso, M.D., will be at the 7th Treg-Directed Therapies Summit in Boston, discussing Treg modulation. Learn more about his participation: bit.ly/4ip2fZU

We are headed to Myasthenia Gravis Foundation of America’s National Patient Conference in Phoenix from March 30 to April 1. Meet our team at booth 211 to discuss the clinical trial evaluating our investigational treatment for #MyastheniaGravis. See you there!

Join us at The American Association of Immunologists (AAI)’s #IMMUNOLOGY2025™ as we present data that demonstrate the potential of our therapies, which are developed using our platform for antigen-specific immune tolerance, to treat #AutoimmuneDiseases. #AAI2025

We will be at Myasthenia Gravis Foundation of America’s Community Health Fair on May 3 in the Tampa Bay Area. Visit our booth to learn more about our investigational treatment for #MyastheniaGravis that is currently being evaluated in a Phase 1b/2a #ClinicalTrial. More here: bit.ly/4c2AgLP

Our Chief Medical Officer, Paul M. Peloso, MD, will join industry leaders on May 21 at 11 am ET to discuss the past, present, and future of treating #Type1Diabetes (#T1D) as part of Technology Networks’ Innovations in Biopharma event. Register here: bit.ly/3Zp2tZj

Our Chief Executive Officer, Dannielle Appelhans, recently joined Annalee Armstrong of BioSpace for a panel alongside several other biotech industry leaders to discuss how companies like COUR are driving innovation despite market uncertainty. Watch here: bit.ly/3Sg65cj

Join us in Irvine, California, at Myasthenia Gravis Foundation of America’s Community Health Fair on Saturday, May 31. Members of our team will be there sharing info on the #ClinicalTrial of our investigational treatment for #MyastheniaGravis. Register here: bit.ly/4mx67u5 #MGCommunity

On June 5, our Chief Medical Officer, Paul M. Peloso, MD, will speak in a panel at BioCentury’s 2nd Grand Rounds in Chicago. He will discuss recent advances of immune tolerization technologies. Learn more about the conference: bit.ly/3FvnR8E

We launched a new website with a refreshed brand that visualizes our work to reprogram the immune system to restore health in people suffering from #AutoimmuneDiseases. Check it out to learn about our platform for antigen-specific immune tolerance: bit.ly/4kGWVlJ

At #FOCIS2025, our Director of Immunology, Joseph Podojil, PhD, and our VP of Research, Adam Elhofy, PhD, will share new data that supports the advancement of therapies based on our platform for antigen-specific immune tolerance. Learn more: bit.ly/43Ux43H

#MyastheniaGravis (MG) is an autoimmune disease that causes fatigue and muscle weakness. As #MGAwarenessMonth comes to an end, we aim to continue education on the symptoms and treatment options, including therapies in clinical development: bit.ly/440ATo2

At COUR, we are building the future of #AutoimmuneDisease treatment without chronic immunosuppression. Our mission fuels everything we do, from breakthrough therapies to bold ideas that align every employee with meaningful, life-changing work. Learn more: bit.ly/45PGU8v